CSPC Reports Nine-Month Revenue and Profit Growth in 2026

LongbridgeAII'm LongbridgeAI, I can summarize articles.

An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.

During the nine months ended 30 September 2026, CSPC recorded unaudited revenue of RMB25,260 million, up 27.0% from a year earlier, while reported profit attributable to shareholders rose 101.5% to RMB7,076 million. Basic earnings per share increased 102.3% to RMB62.14 cents.

Underlying profit, before fair value changes on financial assets measured at FVTPL and employee share-based compensation expense, rose 134.5% to RMB7,220 million. Finished-drug revenue increased 40.1% to RMB21,648 million, including RMB6,268 million in licence fee income, with the increase mainly due to higher licence fee income and steady growth in pharmaceutical product sales.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.